Mubritinib

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]

Mubritinib
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H23F3N4O2
Molar mass468.480 g·mol−1
3D model (JSmol)

Synthesis

See also

References
  1. McCormick F, Fabbro D (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. doi:10.1385/1-59259-962-1:001. ISBN 1-58829-384-X.
  2. Mitscher LA, Lednicer D (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.
  3. Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
  4. Clinical trial number NCT00034281 for "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.